| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 18.04% | Goldman Sachs | $8 → $7 | Maintains | Neutral |
| 07/24/2023 | 34.91% | Goldman Sachs | $9 → $8 | Maintains | Neutral |
| 07/21/2023 | 34.91% | Goldman Sachs | $9 → $8 | Maintains | Neutral |
| 05/15/2023 | 51.77% | Goldman Sachs | $33 → $9 | Maintains | Neutral |
What is the target price for GeneDx Hldgs (WGS)?
The latest price target for GeneDx Hldgs (NASDAQ: WGS) was reported by Goldman Sachs on August 9, 2023. The analyst firm set a price target for $7.00 expecting WGS to rise to within 12 months (a possible 18.04% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for GeneDx Hldgs (WGS)?
The latest analyst rating for GeneDx Hldgs (NASDAQ: WGS) was provided by Goldman Sachs, and GeneDx Hldgs maintained their neutral rating.
When is the next analyst rating going to be posted or updated for GeneDx Hldgs (WGS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GeneDx Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GeneDx Hldgs was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
Is the Analyst Rating GeneDx Hldgs (WGS) correct?
While ratings are subjective and will change, the latest GeneDx Hldgs (WGS) rating was a maintained with a price target of $8.00 to $7.00. The current price GeneDx Hldgs (WGS) is trading at is $5.93, which is out of the analyst's predicted range.